NBC News
NBC News 21 Apr 2020

Scientists Investigate 100-Year-Old Vaccine As Possible COVID-19 Treatment

Description:

Scientists are now looking into a 100-year-old tuberculosis vaccine as a possible treatment for coronavirus. NBC News' Carl Nasman reports on the clinical trials that are already underway.


A herd of goats in California broke out of their enclosure and briefly roamed the streets of San Jose. A 100-year-old COVID-19 survivor gets a special visit on Mother's Day. Here's a roundup of some inspiring news stories from the week.

»»
They're being called "super-agers" - elderly people who somehow manage to survive COVID. There have been a number of people around the age of 100 who have beaten the coronavirus, and researchers want to know why. One theory is that these people simply age slower than others. We spoke with several seniors who are in extraordinary health for their age. One woman, Angelina, was born on a ship on its way to America from Italy, and her family says she has superhuman DNA.
Across the globe, scientists are working hard to come up with a vaccine for COVID-19. Peter Chin-Hong, Professor of Medicine and Infectious Disease Specialist at the University of California, San Francisco, talked about where we are in that process.
Health Secretary Matt Hancock has announced that every care home resident and member of staff in England will be tested for COVID-19 between now and June as the total number of coronavirus-related deaths in the UK rises to 33,998.

Another £600m is now available to care homes in England as a newly-launched service on gov.uk should make it easier for care home managers to source tests, Hancock said.

Defending his government's record, he said two thirds of care homes have not had any cases of COVID-19.

#coronavirus #COVID19 #uk

… show captions ↓
AT A 100-YEAR-OLD TUBERCULOSIS % VACCINE AS A POSSIBLE TREATMENT
VACCINE AS A POSSIBLE TREATMENT FOR THE CORONAVIRUS .
FOR THE CORONAVIRUS . >> IT IS A SHOT IN THE DARK %
>> IT IS A SHOT IN THE DARK % AGAINST COVID-19 .
AGAINST COVID-19 . >> THIS IS THE PRODUCTION OF A
>> THIS IS THE PRODUCTION OF A LIVE VACCINE, BCG NAME FOR %
LIVE VACCINE, BCG NAME FOR % SCIENTIST WHO DEVELOPED IT %
SCIENTIST WHO DEVELOPED IT % NEARLY A CENTURY AGO TO COMBAT %
NEARLY A CENTURY AGO TO COMBAT % TUBERCULOSIS . GOOD AND NOW %
TUBERCULOSIS . GOOD AND NOW % HELP TREAT THE NEW CORONAVIRUS?
HELP TREAT THE NEW CORONAVIRUS? SCIENTISTS ARE RACING TO FIND %
SCIENTISTS ARE RACING TO FIND % OUT . %
OUT . % >> IT IS AN EMERGENCY .
>> IT IS AN EMERGENCY . >> CLINICAL TRIALS ALREADY %
>> CLINICAL TRIALS ALREADY % UNDERWAY IN THE NETHERLANDS AT %
UNDERWAY IN THE NETHERLANDS AT % THE UNIVERSITY MEDICAL CENTER .
THE UNIVERSITY MEDICAL CENTER . PREVIOUS STUDIES HAVE SHOWN IT
PREVIOUS STUDIES HAVE SHOWN IT CAN HELP BOOST IMMUNE SYSTEMS %
CAN HELP BOOST IMMUNE SYSTEMS % AGAINST OTHER INFECTIONS, NOT %
AGAINST OTHER INFECTIONS, NOT % JUST TUBERCULOSIS . SCIENTISTS %
JUST TUBERCULOSIS . SCIENTISTS % HOPE IT CAN ALSO WORK AGAINST %
HOPE IT CAN ALSO WORK AGAINST % THE CORONAVIRUS .
THE CORONAVIRUS . >> THERE IS A GOOD CHANCE THIS %
>> THERE IS A GOOD CHANCE THIS % COULD WORK BUT JUST AS WELL %
COULD WORK BUT JUST AS WELL % LOOK AT HAPPENED THAT THE %
LOOK AT HAPPENED THAT THE % CORONAVIRUS IS VERY DIFFERENT %
CORONAVIRUS IS VERY DIFFERENT % AND THIS VACCINATION CANNOT %
AND THIS VACCINATION CANNOT % PROTECT . %
PROTECT . % >> GLOBALLY VACCINATION %
>> GLOBALLY VACCINATION % PROGRAMS VERY WIDELY. %
PROGRAMS VERY WIDELY. % SOME COUNTRIES GIVE IT TO %
SOME COUNTRIES GIVE IT TO % DIFFERENT AGE GROUPS OR ACROSS %
DIFFERENT AGE GROUPS OR ACROSS % DIFFERENT TIME PERIODS. IN %
DIFFERENT TIME PERIODS. IN % GERMANY THEY STARTED A %
GERMANY THEY STARTED A % NATIONWIDE VACCINE PROGRAM A %
NATIONWIDE VACCINE PROGRAM A % FULL DECADE BEFORE WES GERMANY %
FULL DECADE BEFORE WES GERMANY % . SOME RICHARDS NOW WONDER IF %
. SOME RICHARDS NOW WONDER IF % THERE IS THE LINK BETWEEN HIGHER
THERE IS THE LINK BETWEEN HIGHER RATES AND LOWER RATES OF COVID-%
RATES AND LOWER RATES OF COVID-% 19 . A MAP OF GERMANY’S CASES %
19 . A MAP OF GERMANY’S CASES % SHOWS FAR FEWER INFECTIONS THAN
SHOWS FAR FEWER INFECTIONS THAN THE EAST. %
THE EAST. % THERE IS A SIMILAR PATTERN %
THERE IS A SIMILAR PATTERN % BETWEEN PORTUGAL AND SPAIN .
BETWEEN PORTUGAL AND SPAIN . PORTUGAL STILL USES THE %
PORTUGAL STILL USES THE % VACCINE, SPAIN STOPPED IN 1981.
VACCINE, SPAIN STOPPED IN 1981. THERE ARE MANY OTHER FACTORS %
THERE ARE MANY OTHER FACTORS % THAT PLAY BUT THE BCG LENGTH
THAT PLAY BUT THE BCG LENGTH WAS STRONG ENOUGH FOR THEM TO %
WAS STRONG ENOUGH FOR THEM TO % START RETURN .
START RETURN . >> COUNTRIES THAT NEVER %
>> COUNTRIES THAT NEVER % IMPLEMENTED A BCG VACCINATION %
IMPLEMENTED A BCG VACCINATION % POLICY HAVE HIGHER RATES . THAT
POLICY HAVE HIGHER RATES . THAT COULD BE A CORRELATION.
COULD BE A CORRELATION. IF INDEED THERE IS A CLOSER %
IF INDEED THERE IS A CLOSER % RELATIONSHIP WE NEED TO LOOK %
RELATIONSHIP WE NEED TO LOOK % INTO THAT . %
INTO THAT . % >> WITH TRIALS NOW UNDERWAY AT %
>> WITH TRIALS NOW UNDERWAY AT % LEAST SIX COUNTRIES, THE WORLD %
LEAST SIX COUNTRIES, THE WORLD % HEALTH ORGANIZATION IS URGING %
HEALTH ORGANIZATION IS URGING % CAUTION SAYING IT DOESN’T %
CAUTION SAYING IT DOESN’T % RECOMMEND AS THERE IS NO %
RECOMMEND AS THERE IS NO % CONCRETE EVIDENCE OF PROTECTION
CONCRETE EVIDENCE OF PROTECTION . EVEN IF IT IS NO MAGIC %
. EVEN IF IT IS NO MAGIC % BULLET, ANY POSITIVE EFFECTS %
BULLET, ANY POSITIVE EFFECTS % COULD HELP PROTECT THE MOST %
COULD HELP PROTECT THE MOST % VULNERABLE LIKE HEALTHCARE %

Share Video:

Embed Video: